Nevakar Featured in Global Business Reports
June 12 2017
You previously had great success with InnoPharma, which was eventually sold to Pfizer. Could you provide some insight into your new venture, Nevakar?
InnoPharma’s acquisition was a strategic move by Pfizer; its product pipeline and track record of successfully developing and commercializing complex generic injectable products provided Pfizer a platform for further growth in this area. This was a great exit for InnoPharma’s shareholders as well as its team. After completing integration, I left Pfizer to found Nevakar in 2015.